ILT4-Specific Antibody Binding for Targeted Myeloid Immune Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for cancer lack effective antibodies that specifically target ILT4, a receptor expressed on myeloid cells, and fail to stimulate T cell activation and promote pro-inflammatory responses in immune cells.

Innovation Solution

Development of antibodies that specifically bind to ILT4, stimulating T cell activation, promoting pro-inflammatory macrophage differentiation, and enhancing cytokine secretion, while minimizing cross-reactivity with other LILRA and LILRB family members.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current cancer treatments are used, then general cancer therapy is provided, but effective ILT4-specific targeting is lacking

Engineering Contradiction:

ImproveILT4 targeting specificityVSAvoidcancer treatment effectiveness

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent segments the immune system targeting by specifically designing antibodies that bind only to ILT4 receptor on myeloid cells, separating this target from other immune checkpoints like PD-1/PD-L1. This specificity allows precise intervention in the ILT4-mediated immunosuppression pathway without affecting other immune mechanisms.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The antibodies are designed with specific binding characteristics that target only ILT4-expressing myeloid cells while sparing other cell types. This local quality approach ensures that the therapeutic effect is concentrated on the specific pathogenic population (ILT4+ myeloid cells) without causing widespread immune activation or off-target effects.

Inventive Principle:

Principle #3Local quality

2Reliability

If antibodies stimulate T cell activation and pro-inflammatory responses, then cancer immunotherapy effectiveness is improved, but cross-reactivity with other LILRA and LILRB family members increases

Engineering Contradiction:

Improveimmune activation effectivenessVSAvoidcross-reactivity with LILRA/LILRB family

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The antibody design segments the LILR family targeting by achieving high specificity for ILT4 (LILRB2) while deliberately avoiding binding to other LILRA and LILRB family members. This segmentation prevents off-target effects on other immune receptors that share structural similarities.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The antibodies exhibit local quality in their binding properties, with high affinity and specificity for ILT4's unique epitopes while showing negligible cross-reactivity with other LILR family members. This selective binding profile ensures that immune activation is directed precisely at ILT4+ myeloid cells without triggering unintended immune responses through cross-reactivity.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS12435136B2Antibodies binding to ILT4

Publication Date: 2025.10.07 BRISTOL MYERS SQUIBB CO

AI summary

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.